Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.

Autor: Eyre TA; Department of Haematology, Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Jensen P; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark., Booth S; Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK., El-Galaly TC; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2022 Aug; Vol. 198 (3), pp. 431-442. Date of Electronic Publication: 2022 Mar 02.
DOI: 10.1111/bjh.18104
Abstrakt: With survival outcomes ever improving for patients with a wide range of lymphoma histologies, the focus on reducing long-term complications of therapy has increased. Recently published, complimentary population and retrospective series have highlighted the importance of considering bone health in patients treated for lymphoma. Fracture-related events or the requirement for secondary bone prophylaxis, likely linked to glucocorticoid-induced osteoporosis (GIO) are substantial and clinically meaningful in a significant minority of patients following routinely employed steroid-containing immunochemotherapy. In this review, we describe the pathophysiology of GIO, the risk of GIO in observational front-line lymphoma studies and efficacy of prophylactic measures from several prospective clinical trials are summarized. Finally, areas of importance for future research are discussed and recommendations for GIO risk assessment and management in lymphoma are provided based on the current available literature.
(© 2022 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: